Chronic Spontaneous Urticaria Market Report 2026

The chronic spontaneous urticaria market size has grown strongly in recent years. It will grow from $2.23 billion in 2025 to $2.41 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of chronic skin allergies, wider availability of second-generation antihistamines, improved diagnostic practices, growth in dermatology clinic visits, increased patient awareness of urticaria conditions.

The chronic spontaneous urticaria market size is expected to see strong growth in the next few years. It will grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing biologic drug pipeline development, rising investment in autoimmune dermatology research, expansion of targeted monoclonal antibody use, growing focus on symptom-free disease control, increasing adoption of long-term maintenance therapies. Major trends in the forecast period include increasing adoption of biologic treatments for csu, rising use of advanced antihistamine protocols, growing focus on autoimmune disease mechanisms, expansion of personalized treatment algorithms, enhanced monitoring of long-term disease control.

Increasing alcohol consumption is expected to drive the growth of the chronic spontaneous urticaria market in the coming years. The rising intake of alcohol can be attributed to factors such as social norms, stress, marketing influence, affordability, and easy availability. Alcohol consumption may worsen symptoms of chronic spontaneous urticaria in certain individuals, leading to more frequent or severe episodes of hives and swelling. For instance, in 2025, according to the Priory Group, a UK-based provider of mental health, addiction, and specialist education services, a 2023 survey reported that 25% of individuals aged 18-24 in the UK now abstain from alcohol completely, indicating a notable shift toward sobriety among younger people. Therefore, increasing alcohol consumption is contributing to the growth of the chronic spontaneous urticaria market.

Major companies operating in the chronic spontaneous urticaria market are focusing on the development of advanced next-generation therapies such as Briquilimab (JSP191) to improve treatment effectiveness and reduce dosing frequency. Next-generation Briquilimab (JSP191) is a monoclonal antibody designed to target and deplete specific immune cells by acting on CD47, with potential applications in chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a US-based clinical-stage biotechnology company, announced that it had dosed the first patient in a Phase 1b/2a clinical trial of Briquilimab for the treatment of chronic spontaneous urticaria. This milestone represents an important step in evaluating the safety and efficacy of Briquilimab, a next-generation monoclonal antibody targeting CD47, for managing recurrent hives and itching. The study aims to assess the therapy’s ability to reduce symptoms and improve quality of life for patients with chronic spontaneous urticaria.

In May 2024, Incyte Corporation, a US-based biopharmaceutical company focused on developing and commercializing innovative medicines, acquired Escient Pharmaceuticals for an undisclosed amount. Through this acquisition, Incyte seeks to expand its immunology and inflammation pipeline, strengthen its early-stage research and development capabilities, and accelerate the advancement of first-in-class therapies targeting sensory modulation pathways. Escient Pharmaceuticals is a US-based clinical-stage biotechnology company specializing in novel small-molecule therapeutics for chronic inflammatory and allergic diseases.

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

North America was the largest region in the chronic spontaneous urticaria market in 2025. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic spontaneous urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic spontaneous urticaria market by increasing costs of imported biologics, antihistamines, diagnostic reagents, and pharmaceutical manufacturing inputs. North America and Europe are most affected due to dependence on biologic drug imports, while Asia-Pacific faces production cost inflation for export-oriented therapies. These tariffs are influencing treatment pricing and reimbursement structures. However, they are also encouraging domestic biologic manufacturing, regional clinical development, and diversification of pharmaceutical supply chains to improve long-term market stability.

The chronic spontaneous urticaria market research report is one of a series of new reports that provides chronic spontaneous urticaria market statistics, including chronic spontaneous urticaria industry global market size, regional shares, competitors with a chronic spontaneous urticaria market share, detailed chronic spontaneous urticaria market segments, market trends and opportunities, and any further data you may need to thrive in the chronic spontaneous urticaria industry. This chronic spontaneous urticaria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic spontaneous urticaria (CSU) is a skin disorder marked by the recurrent occurrence of hives, which are raised, red, itchy welts, and angioedema, or swelling, that persist for more than six weeks without a clearly identifiable external trigger. The exact cause of CSU is often unclear, but it may involve an autoimmune mechanism in which the immune system mistakenly targets healthy skin cells. Management of the condition focuses on controlling symptoms, primarily through the use of antihistamines and, in more severe cases, additional therapies such as biologics.

The primary treatment options for chronic spontaneous urticaria include medications, phototherapy, and other approaches. Medications for chronic spontaneous urticaria generally involve antihistamines as the first-line therapy, with both non-sedating and sedating options selected based on symptom severity and patient response. Treatments can be administered through oral, topical, parenteral, and other routes. Diagnosis typically includes physical examination, blood tests, and allergy testing, and these treatments are utilized across various end users, including hospitals, specialty clinics, home care settings, and others.

The chronic spontaneous urticaria market consists of revenues earned by entities by providing services such as diagnostic services and medical consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic spontaneous urticaria market also includes sales of antihistamines, corticosteroids, and cyclosporine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.